Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Top.GainersTop.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
10 Mar 2025Redfin $RDFN stole the spotlight today, surging 67.87% after mortgage giant Rocket Companies $RKT announced a blockbuster $1.75 billion all-stock acquisition of the online real estate brokerage. This deal consolidates mortgage lending and home listings under one roof, giving Rocket a significant competitive edge in the housing market. Redfin shareholders will receive 0.7926 shares of Rocket Class A stock per Redfin share, marking a 63% premium over its 30-day volume-weighted average price. The result? A high-volume breakout, with over 92 million shares traded, dwarfing its 6.78 million average. Investors are clearly bullish on the strategic synergy, betting that Rocket’s deep mortgage expertise will supercharge Redfin’s homebuying platform.
Checkpoint Therapeutics $CKPT also rocketing 61.13% following news that Sun Pharma—India’s largest pharmaceutical company—would acquire the oncology-focused biotech firm for $355 million. This deal strengthens Sun Pharma’s oncology and dermatology portfolio, offering a pathway for Checkpoint’s immunotherapy pipeline to reach a broader global market. With 61 million shares traded, well above its 736,000 average, the acquisition ignited speculative buying, pushing CKPT to levels unseen in months.
Mineralys Therapeutics $MLYS surged 42.21% after unveiling strong Phase 2 and Phase 3 trial results for its hypertension drug lorundrostat. The treatment met key efficacy endpoints, showing a significant reduction in systolic blood pressure. With hypertension being a massive global market, investors see blockbuster potential for Mineralys, explaining today’s massive 14.77 million share volume, which dwarfed its 332,000 average. The stock’s bullish breakout suggests momentum traders are piling in, expecting further gains as the drug progresses toward regulatory approval.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
